Aspen Pharmacare to Sell Ovestin European Rights for €197 Million
Aspen Pharmacare will sell Ennogen Healthcare International the European commercialisation rights and related intellectual property for its women's health product Ovestin for €197 million ($220 million).
By Nqobile DludlaSouth Africa's Aspen Pharmacare JSE:APN will sell the European commercialisation rights and related intellectual property for its women's health product Ovestin to Ennogen Healthcare International for €197 million ($220 million), it said on Monday.($1 = 0.8948 euros)($1 = 16.6981 r…